For more information on our recent data notice, please click here

Menu
Search

UC San Diego Cancer Scientists Identify New Drug Target for Multiple Tumor Types

A dysfunctional enzyme involved in building cancer cell membranes helps fuel tumor growth; when it’s disabled or depleted in mouse models, tumors shrank significantly

July 11, 2019  |  

​A research team headed by scientists at University of California San Diego School of Medicine and the Ludwig Institute for Cancer Research at UC San Diego has identified an enzyme involved in remodeling the plasma membrane of multiple cancer cell types that is critical to both survival of tumors and their uncontrolled growth.

The finding, published in the July 11, 2019 issue of Cell Metabolism, suggests a potential target for new drugs.

“Cancers are characterized not only by major changes in their genomes, but also by profound shifts in how they take up and utilize nutrients to propel rapid tumor growth,” said senior author Paul S. Mischel, MD, professor in the UC San Diego School of Medicine Department of Pathology and Ludwig member. “How do these diverse aspects fit together and can they be taken advantage of, for the benefit of patients?”

electron micrograph of cancer cells

A false color electron micrograph of two cancer cells. Image courtesy of Thomas Deerinck, National Center for Microscopy and Imaging Research, UC San Diego.

In the new study, conducted in collaboration with Benjamin Cravatt, PhD, professor at Scripps Research, and led by first author Junfeng Bi, PhD, in Mischel’s lab, researchers identified an enzyme called LPCAT1, whose levels increase in cancer and which plays a key role in tumor growth by changing the phospholipid composition of the cancer cells’ plasma membrane, allowing amplified and mutated growth factor signals to spur tumor growth.

Without LPCAT1, tumors cannot survive. When researchers genetically depleted LPCAT1 in multiple types of cancer in mice, including highly lethal glioblastomas (brain) and an aggressive lung cancer, malignancies shrank dramatically and survival times improved.

The results, wrote the authors, demonstrate that LPCAT1 is an important enzyme that becomes dysregulated in cancer, linking common genetic alterations in tumors with changes in their metabolism to drive aggressive tumor growth.”

“Advances in DNA sequencing technologies have reshaped our understanding of the molecular basis of cancer, suggesting a new and more effective way of treating cancer patients,” said Mischel. “However, to date, precision oncology has yet to benefit many patients, motivating a deeper search into understanding how genetic alterations in tumors change the way cancer cells behave, and potentially unlocking new ways to more effectively treat patients.

“These results also suggest that LPCAT1 may be a very compelling new drug target in a wide variety of cancer types.”

Co-authors include: Taka-Aki Ichu and Alex Reed, Skaggs Research; Ciro Zanca, Huijun Yang, Sudhir Chowdhry, Kristen M. Turner, Wenjing Zhang and Sihan Wu, Ludwig Institute for Cancer Research; Wei Zhang, Oswald Quehenberger, Jeremy N. Rich, Webster K. Cavenee and Frank B. Furnari, UC San Diego; Yuchao Gu and Genaro R. Villa, Ludwig and UCLA; Shiro Ikegami, Chiba University; William H. Yong, Harley I. Kornblum, and Timothy F. Cloughesy, UCLA.

Funding for this research came, in part, from the Ludwig Institute for Cancer Research, the National Institute for Neurological Diseases and Stroke (grant NS73831), the Defeat GBM Program of the National Brain Tumor Society, the Ben and Catherine Ivy Foundation, the Sharpe/National Brain Tumor Society Research Program, the Nvidia Foundation and the UC San Diego Neuroscience Microscopy Shared Facility grant (P30 NS047101).

Disclosure: Paul Mischel is co-founder of Pretzel Therapeutics. He has equity and serves as a consultant for the company. He also did one-time consultation for Abide Therapeutics.


​Care at UC San Diego Health

Cancer Services



Media Contact

Scott LaFee
858-249-0431
slafee@health.ucsd.edu

Share This Article


Related News

3/20/2019
UC San Diego School of Medicine research sets the stage for clinicians to potentially one day use levels of a pancreatic cancer patient’s PHLPP1 and PKC enzymes as a prognostic, and for researchers to ...
5/1/2018
The All of Us Research Program officially opens for enrollment Sunday, May 6. Led by the National Institutes of Health (NIH), All of Us is an unprecedented effort to gather genetic, biological, enviro ...
3/20/2017
Genetic mutations that cause cancer also weaken cancer cells, allowing researchers to develop drugs that will selectively kill them. This is called “synthetic lethality” because the drug is only letha ...
2/1/2017
In a new paper published this week in PNAS, researchers describe a potential new class of anti-cancer drugs that inhibit two or more molecular targets at once, maximizing therapeutic efficiency and sa ...



Follow Us